Caffeine and Cerebrovascular Reactivity

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Caffeine is the most commonly used stimulant drug with well documented effects on cerebral vascula-ture. Caffeine is known to non-specifically bind to adenosine receptors in the brain and to reduce resting blood flow while improving attention and cognitive function, which suggests that it may allow a more efficient dynamic blood flow regulation through neurovascular coupling. This study will use standardized dose of caffeine to test its effect on NVC responses in cerebral and retinal arterioles.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Oklahoma
• Treatments: Caffeine

Criteria

Inclusion Criteria:

• English speaking

• Ability to read and write in English

• Competence to provide informed consent

• Non-occludable angle and with no optic neuropathy

• Subjects will be asked to refrain from caffeine consumption for at least 8 hours before participating in the study

Exclusion Criteria:

• The history of photosensitive epilepsy

• Intraocular pressure 21 Hgmm or higher

• Eyes with a visual acuity 20/30 or lower or the inability to fixate on fixation markers

• Previous symptoms of glaucoma attack (severe ocular pain and redness, decreased vision, colored halos in combination with headache, nausea and vomiting).

• Known allergies to study drugs

• Pregnancy and breast feeding

• Significant cardiac disease (e.g. heart failure), chest pain in the last 6 months

• Stage-2 high blood pressure not controlled by medication (>160/100 mm Hg)

• Uncontrolled diabetes mellitus; History of stroke; Multiple sclerosis; Chronic obstructive pulmonary disease; Active cancer; Abnormal liver function

• Diagnosis of dementia; Anxiety Disorder

• Absent temporal acoustic windows, intracranial stenosis (for TCD-related studies)

• History of arrhythmias

• Prisoners